290 related articles for article (PubMed ID: 34882052)
1. Clinical outcomes, molecular epidemiology and resistance mechanisms of multidrug-resistant
Sid Ahmed MA; Hamid JM; Husain AA; Hadi HA; Skariah S; Sultan AA; Ibrahim EB; Al Khal AL; Soderquist B; Jass J; Omrani AS
Ann Med; 2021 Dec; 53(1):2345-2353. PubMed ID: 34882052
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar.
Sid Ahmed MA; Abdel Hadi H; Hassan AAI; Abu Jarir S; Al-Maslamani MA; Eltai NO; Dousa KM; Hujer AM; Sultan AA; Soderquist B; Bonomo RA; Ibrahim EB; Jass J; Omrani AS
J Antimicrob Chemother; 2019 Dec; 74(12):3497-3504. PubMed ID: 31504587
[TBL] [Abstract][Full Text] [Related]
3. β-lactamase-mediated resistance in MDR-Pseudomonas aeruginosa from Qatar.
Sid Ahmed MA; Khan FA; Sultan AA; Söderquist B; Ibrahim EB; Jass J; Omrani AS
Antimicrob Resist Infect Control; 2020 Nov; 9(1):170. PubMed ID: 33131487
[TBL] [Abstract][Full Text] [Related]
4. Co-harboring of mcr-1 and β-lactamase genes in Pseudomonas aeruginosa by high-resolution melting curve analysis (HRMA): Molecular typing of superbug strains in bloodstream infections (BSI).
Tahmasebi H; Dehbashi S; Arabestani MR
Infect Genet Evol; 2020 Nov; 85():104518. PubMed ID: 32891877
[TBL] [Abstract][Full Text] [Related]
5. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
Henderson A; Tan E; McCarthy KL; Paterson DL
Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-2009 study.
McCracken M; Mataseje LF; Loo V; Walkty A; Adam HJ; Hoban DJ; Zhanel GG; Mulvey MR;
Diagn Microbiol Infect Dis; 2011 Mar; 69(3):335-41. PubMed ID: 21353962
[TBL] [Abstract][Full Text] [Related]
7. Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa.
Tam VH; Chang KT; Abdelraouf K; Brioso CG; Ameka M; McCaskey LA; Weston JS; Caeiro JP; Garey KW
Antimicrob Agents Chemother; 2010 Mar; 54(3):1160-4. PubMed ID: 20086165
[TBL] [Abstract][Full Text] [Related]
8. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and microbiological and genetic characteristics of multidrug-resistant
Sid Ahmed MA; Abdel Hadi H; Abu Jarir S; Ahmad Khan F; Arbab MA; Hamid JM; Alyazidi MA; Al-Maslamani MA; Skariah S; Sultan AA; Al Khal AL; Söderquist B; Ibrahim EB; Jass J; Ziglam H
Antimicrob Steward Healthc Epidemiol; 2022; 2(1):e96. PubMed ID: 36483382
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of fortimicin antibiotic combinations against MDR Pseudomonas aeruginosa and resistome analysis of a whole genome sequenced pan-drug resistant isolate.
Kamel NA; Tohamy ST; Alshahrani MY; Aboshanab KM
BMC Microbiol; 2024 May; 24(1):164. PubMed ID: 38745145
[TBL] [Abstract][Full Text] [Related]
11. Genomics of Aminoglycoside Resistance in Pseudomonas aeruginosa Bloodstream Infections at a United States Academic Hospital.
Atassi G; Medernach R; Scheetz M; Nozick S; Rhodes NJ; Murphy-Belcaster M; Murphy KR; Alisoltani A; Ozer EA; Hauser AR
Microbiol Spectr; 2023 Jun; 11(3):e0508722. PubMed ID: 37191517
[TBL] [Abstract][Full Text] [Related]
12. Identification of nonclonal Pseudomonas aeruginosa isolates with reduced colistin susceptibility in Korea.
Lee JY; Song JH; Ko KS
Microb Drug Resist; 2011 Jun; 17(2):299-304. PubMed ID: 21381965
[TBL] [Abstract][Full Text] [Related]
13. Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain.
Del Barrio-Tofiño E; López-Causapé C; Cabot G; Rivera A; Benito N; Segura C; Montero MM; Sorlí L; Tubau F; Gómez-Zorrilla S; Tormo N; Durá-Navarro R; Viedma E; Resino-Foz E; Fernández-Martínez M; González-Rico C; Alejo-Cancho I; Martínez JA; Labayru-Echverria C; Dueñas C; Ayestarán I; Zamorano L; Martinez-Martinez L; Horcajada JP; Oliver A
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874376
[TBL] [Abstract][Full Text] [Related]
14. High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial.
Pérez A; Gato E; Pérez-Llarena J; Fernández-Cuenca F; Gude MJ; Oviaño M; Pachón ME; Garnacho J; González V; Pascual Á; Cisneros JM; Bou G
J Antimicrob Chemother; 2019 May; 74(5):1244-1252. PubMed ID: 30753505
[TBL] [Abstract][Full Text] [Related]
15. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
Hu YF; Liu CP; Wang NY; Shih SC
BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
[TBL] [Abstract][Full Text] [Related]
16. Epidemiological, Physiological, and Molecular Characteristics of a Brazilian Collection of Carbapenem-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa.
Dias VC; Resende JA; Bastos AN; De Andrade Bastos LQ; De Andrade Bastos VQ; Bastos RV; Diniz CG; Da Silva VL
Microb Drug Resist; 2017 Oct; 23(7):852-863. PubMed ID: 28437232
[TBL] [Abstract][Full Text] [Related]
17. Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers.
Giani T; Arena F; Pollini S; Di Pilato V; D'Andrea MM; Henrici De Angelis L; Bassetti M; Rossolini GM;
J Antimicrob Chemother; 2018 Mar; 73(3):664-671. PubMed ID: 29216350
[TBL] [Abstract][Full Text] [Related]
18. Detection of synergistic antimicrobial resistance mechanisms in clinical isolates of Pseudomonas aeruginosa from post-operative wound infections.
Awan AB; Yan A; Sarwar Y; Schierack P; Ali A
Appl Microbiol Biotechnol; 2021 Dec; 105(24):9321-9332. PubMed ID: 34797390
[TBL] [Abstract][Full Text] [Related]
19. Laboratory based antimicrobial resistance surveillance for Pseudomonas aeruginosa blood isolates from South Africa.
Singh-Moodley A; Duse A; Naicker P; Kularatne R; Nana T; Lekalakala R; Mbelle N; Dawood H; Swe Swe Han K; Ramjathan P; Bhola P; Whitelaw A; Perovic O
J Infect Dev Ctries; 2018 Aug; 12(8):616-624. PubMed ID: 31958323
[TBL] [Abstract][Full Text] [Related]
20. Drug resistance profile and molecular characterization of extended spectrum beta-lactamase (ESβL)-producing Pseudomonas aeruginosa isolated from burn wound infections. Essential oils and their potential for utilization.
El-Shouny WA; Ali SS; Sun J; Samy SM; Ali A
Microb Pathog; 2018 Mar; 116():301-312. PubMed ID: 29407236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
